3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
87
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Recurrence
16
Burkitt Lymphoma
13
Neoplasms
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Biphenotypic, Acute
7
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
6
Lung Neoplasms
6
Immunoglobulin Light-chain Amyloidosis
6
Neoplasms, Plasma Cell
5
Hodgkin Disease
5
Smoldering Multiple Myeloma
4
Leukemia
4
Carcinoma, Non-Small-Cell Lung
4
Waldenstrom Macroglobulinemia
3
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Neoplasm Metastasis
3
Nausea
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Brain Neoplasms
3
Renal Insufficiency
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, B-Cell
2
Leukemia, Plasma Cell
2
Interventions
Carboplatin
18
Paclitaxel
17
Bevacizumab
17
olaparib
8
Specimen Handling
7
liposomal doxorubicin
6
pembrolizumab
5
Taxes
5
Biopsy
5
cemiplimab
4
Magnetic Resonance Spectroscopy
4
sarilumab
3
niraparib
3
mirvetuximab soravtansine
3
Topotecan
3
Standard of Care
3
Letrozole
3
Gemcitabine
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
taxane
2
talazoparib
2
palbociclib
2
abemaciclib
2
Temozolomide
2
Surgical Procedures, Operative
2
Practice Guidelines as Topic
2
Poly(ADP-ribose) Polymerase Inhibitors
2
Immunoglobulin G
2
Fulvestrant
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Fallopian Tube Neoplasms
×
Dexamethasone
×
Clear all
NCT06824467
2026-05-08
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled